

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7707591

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
GALARY, INC	04/25/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	GALVANIZE THERAPEUTICS, INC.
<b>Street Address:</b>	1531 INDUSTRIAL ROAD
<b>City:</b>	SAN CARLOS
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94070
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	18077097
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	jroeder@wsgr.com, patentedocket@wsgr.com
<b>Correspondent Name:</b>	WILSON SONSINI GOODRICH & ROSATI
<b>Address Line 1:</b>	650 PAGE MILL ROAD
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94304
<b>NAME OF SUBMITTER:</b>	JOY A. ROEDER
<b>SIGNATURE:</b>	/Joy A. Roeder/
<b>DATE SIGNED:</b>	12/21/2022
<b>Total Attachments: 4</b>	
source=Assignment Galary to Galvanize#page1.tif	
source=Assignment Galary to Galvanize#page2.tif	
source=Assignment Galary to Galvanize#page3.tif	
source=Assignment Galary to Galvanize#page4.tif	

**CORPORATE TO CORPORATE PATENT ASSIGNMENT**

Docket Number 58880-700

Galary, Inc., having a place of business at 1531 Industrial Road, San Carlos, CA, 94070, (the "Assignor"), hereby desires to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Galvanize Therapeutics, Inc., a Delaware Corporation, having a place of business at 1531 Industrial Road, San Carlos, CA, 94070, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor has obtained the entire right, title and interest in and to certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

**SEE EXHIBIT A ATTACHED HERETO**

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

3. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.

4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, and assigns, and shall be binding upon said Assignor and its assigns.

5. Said Assignor hereby warrants, represents and covenants that Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

6. Said Assignor hereby requests that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors and assigns.

7. This instrument will be interpreted and construed in accordance with the laws of the [Name of State / Commonwealth / Country], without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below:

AGREED TO BY ASSIGNOR: Galary, Inc.

04/25/22

Date: \_\_\_\_\_

Signature:  \_\_\_\_\_

Name: Jonathan Waldstreicher

Title: CEO

RECEIVED AND AGREED TO BY ASSIGNEE: Galvanize Therapeutics, Inc.

04/25/22

Date: \_\_\_\_\_

Signature:  \_\_\_\_\_

Name: Jonathan Waldstreicher

Title: CEO

## EXHIBIT A

Case Number	Subcase	Application Number	Filing Date	Patent Number	Issue Date
58880-703	101	62/355,164	27-Jun-2016		
58880-703	102	62/489,753	25-Apr-2017		
58880-703	301	16/227,796	20-Dec-2018		
58880-703	302	16/381,745	11-Apr-2019	10,702,337	07-Jul-2020
58880-703	303	16/898,320	10-Jun-2020	10,939,958	09-Mar-2021
58880-703	601	PCT/US2017/039527	27-Jun-2017		
58880-704	101	62/610,430	26-Dec-2017		
58880-704	301	16/914,072	26-Jun-2020		
58880-704	302	17/214,688	26-Mar-2021		
58880-704	601	PCT/US2018/067501	26-Dec-2018		
58880-705	101	62/693,622	03-Jul-2018		
58880-705	301	16/914,200	26-Jun-2020		
58880-705	601	PCT/US2018/067504	26-Dec-2018		
58880-706	101	62/835,846	18-Apr-2019		
58880-706	301	17/502,640	15-Oct-2021		
58880-706	601	PCT/US2020/028844	17-Apr-2020		
58880-707	101	62/874,605	16-Jul-2019		
58880-707	301	17/575,500	13-Jan-2022		
58880-707	601	PCT/US2020/042260	16-Jul-2020		
58880-708	101	62/902,004	18-Sep-2019		
58880-708	102	63/076,536	10-Sep-2020		
58880-708	103	63/241,241	07-Sep-2021		
58880-709	101	62/949,633	18-Dec-2019		
58880-709	301	17/466,871	03-Sep-2021		
58880-709	601	PCT/US2020/066205	18-Dec-2020		
58880-710	101	62/994,620	25-Mar-2020		
58880-710	501	17/212,833	25-Mar-2021		
58880-711	101	63/000,275	26-Mar-2020		
58880-712	101	63/007,233	08-Apr-2020		
58880-712	102	63/078,784	15-Sep-2020		
58880-712	601	PCT/US2021/026221	07-Apr-2021		
58880-713	101	63/061,091	04-Aug-2020		
58880-713	601	PCT/US2021/044469	04-Aug-2021		
58880-714	101	63/061,114	04-Aug-2020		
58880-715	101	63/083,644	25-Sep-2020		
58880-716	101	63/159,331	10-Mar-2021		
58880-716	601	PCT/US2022/019719	10-Mar-2022		
58880-717	101	63/166,145	25-Mar-2021		
58880-717	601	PCT/US2022/021888	25-Mar-2022		
58880-718	101	63/178,174	22-Apr-2021		
58880-719	101	63/189,358	17-May-2021		
58880-720	101	63/209,319	10-Jun-2021		
58880-721	101	63/209,335	10-Jun-2021		
58880-721	601	PCT/US2022/015217	04-Feb-2022		
58880-723	101	63/246,239	20-Sep-2021		
58880-723	102	63/322,319	22-Mar-2022		
58880-724	101	63/282,521	23-Nov-2021		
58880-725	101	63/290,529	16-Dec-2021		

This audit trail was created during the document signature process and holds details of parties involved, including email address of signer(s), device IPs, signature timestamp and more. It serves as a digital certificate and can be used as a legal evidence.

DOCUMENT	Galaxy to Galvanize 58880-700.pdf
INITIATOR EMAIL	lynne@galatherapeutics.com
INITIATOR REFERENCE ID	d0e580a12e314d1f532528424ad4fd12

DOCUMENT NAME	FINGERPRINT	REFERENCE ID	VERIFICATION LINK
Galaxy to Galvanize	3abd089e545446e298	5d6a5f67bed845d8ab5	<a href="#">Click to verify</a>
58880-700.pdf	a8e8a08ba0d96664fa9	d04dc646247ee	
	7a64a31ea75ec948d68		
	6244df5b		




**LEGAL**

Electronic signature are legally binding and admissible in a court of law in accordance with the ESIGN Act in United States and eIDAS in the European Union. Most of the other countries around the world as well have adopted an electronic signature law or have recognized electronic signatures for business or personal transactions.



**SECURE**

This document was securely processed using 256 bit SSL encryption technology for the communication channels between your device and the secure servers hosted at Amazon Web Services, which is ISO 27001 compliant.



**TRUST**

Signeasy is trusted and used by thousands of companies and millions of people in over 150 countries.



Learn more at: <https://signeasy.com>



Signature request initiated for:  
**Jon@GalaTherapeutics.com (Jonathan Waldstreicher)**

Initiated on: 2022-04-21 21:09:53 UTC  
IP: 107.214.150.85



**Signed by jon@galatherapeutics.com (Jonathan Waldstreicher)**

Signed on: 2022-04-25 12:42:22 UTC  
IP: 108.53.211.253



**Signature request completed.**

Completed on: 2022-04-25 12:42:24 UTC  
IP: 108.53.211.253